In this paper, Robert Lins, MD, PhD, Respiratory Project Director
at SGS, illustrates how respiratory drug development has, for years,
been relying on the administration of new, mostly inhaled drugs,
and on assessment by physiologic tests and questionnaires. The
physiologic outcomes were mostly lung function tests; gradually
more clinical and patient-reported outcomes have been applied.
New insights in phenotypes, endotypes, basic mechanisms, and
new targets for therapy have led to the need for more personalised,